Adiponectin receptor agonists inhibit leptin induced pSTAT3 and in vivo pancreatic tumor growth

Fanuel Messaggio, Alisha M. Mendonsa, Jason Castellanos, Nagaraj S. Nagathihalli, Lee Gorden, Nipun B. Merchant, Michael N. VanSaun

Research output: Contribution to journalArticlepeer-review

24 Scopus citations


Obesity is a significant risk factor for pancreatic cancer, harboring a chronic inflammatory condition characterized by dysregulation of the adipokines, leptin and adiponectin, that in turn alter oncogenic signaling pathways. We and others have shown that leptin promotes the proliferation and an invasive potential of pancreatic cancer cells through STAT3 mediated signaling. However, the role of adiponectin on the tumorigenicity of pancreatic cancer has not been elucidated. Adiponectin represents an important negative regulator of cytokines, which acts through two receptors, ADIPOR1 and ADIPOR2, to elicit pro-apoptotic, anti-inflammatory, and anti-angiogenic responses. We show that the level and expression of both adiponectin receptors are decreased in pancreatic tumors relative to normal pancreatic tissue. In vitro stimulation with adiponectin or a small molecule adiponectin receptor agonist, AdipoRon, increases apoptosis while inhibiting pancreatic cancer cell proliferation, colony formation, and anchorage independent growth. In addition, adiponectin receptor agonism inhibits leptin mediated STAT3 activation. In vivo, treatment of mice with AdipoRon inhibits orthotopic pancreatic tumor growth. These results demonstrate that adiponectin receptor activation is a key regulator of pancreatic cancer growth and AdipoRon provides a rational agent for the development of novel therapeutic strategies for pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)85378-85391
Number of pages14
Issue number49
StatePublished - Oct 17 2017


  • AdipoRon
  • Adipokine
  • Adiponectin
  • Pancreatic adenocarcinoma
  • STAT3

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Adiponectin receptor agonists inhibit leptin induced pSTAT3 and in vivo pancreatic tumor growth'. Together they form a unique fingerprint.

Cite this